Factor VIII anticorps

N° du produit ABIN112268

L’anticorps Souris Monoclonal anti-Factor VIII a été validé pour WB, IHC (fro) et EIA. Il convient pour détecter Factor VIII dans des échantillons de Humain.

Aperçu rapide pour Factor VIII anticorps (ABIN112268)

Antigène: Factor VIII (F8) (Coagulation Factor VIII (F8))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Factor VIII est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)

Clone: MH104

Détail du produit anti-Factor VIII anticorps

Specificité: MH104 is specific for human factor VIIIc, a 300 kDa protein present in plasma in a complex with von Willebrandt factor. Involved in the clotting cascade (activated by thrombin) by forming a complex with factor IXa, calcium, and phospholipids. Elevated levels of factor VIII have been associated with acute and chronic liver diseases, vascular disorders, diabetes and with acutephase reactions.

Purification: Protein A affinity chromatography

Immunogène: Human factor VIII antigen

Isotype: IgG2a

Information d'application

Indications d'application: ELISA: 1: 5,000, detection and quantitation of human factor VIII. Immunoblotting. Immunohistochemistry on frozen sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Reconstitution: Restore in 1 mL dist. water

Buffer: PBS, pH 7.4 containing 0.09 % NaN3, 0.5 % BSA

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: This product is photosensitive and should be protected from light

Stock: 4 °C

Stockage commentaire: Prior to and following reconstitution store the antibody undiluted at 2-8 °C. DO NOT FREEZE!

Détails sur Factor VIII

Antigène: Factor VIII (F8) (Coagulation Factor VIII (F8))

Sujet: Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50 % of patients have severe hemophilia A with F8C activity less than 1 % of normal, they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10 % of patients, F8C activity is 2-5 % of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40 % of patients, is associated with F8C activity of 5-30 % and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5 %) that have considerable amount of F8C in their plasma (at least 30 % of normal), but the protein is nonfunctional, i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.Synonyms: AHF, Antihemophilic factor, F8C, Procoagulant component

ID gène: 2157

NCBI Accession: NP_000123

UniProt: P00451